Crinetics Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
Crinetics Pharmaceuticals, Inc. (CRNX) had Debt Securities, Available-for-sale, Unrealized Loss Position of $86.67 million as of 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2025-11-06
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $86.67M.
- 2025-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $135.00K.
- 2025-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $87.00K.
- 2024-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $232.92M; Debt Securities, Available-for-sale, Unrealized Loss Position as first filed $274.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position | Debt Securities, Available-for-sale, Unrealized Loss Position as first filed |
|---|---|---|
| 2025-09-30 | $86.67M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $135.00K 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $87.00K 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $232.92M 10-Q · filed 2025-11-06 | $274.00K 10-K · filed 2025-02-27 |
| 2024-09-30 | $25.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $322.00K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $243.00K 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $298.00K 10-K · filed 2025-02-27 | |
| 2023-09-30 | $918.00K 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $1.72M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $2.53M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $3.94M 10-K · filed 2024-02-28 |